Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy

Circulation Research

Volumn 82, Issue 1, 1998, Pages 57-62

  Schäfers, Michael ^b   Dutka, David ^a   Rhodes, Christopher G ^a   Lammertsma, Adriaan A ^a   Hermansen, Flemming ^a   Schober, Otmar ^b   Camici, Paolo G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Autonomic dysfunction; Beta adrenoceptors; Cardiomyopathy, hypertrophic; Catecholamines; Positron emission tomography

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART INNERVATION; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; SYMPATHETIC INNERVATION;

EID: 0038589774     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.1.57     Document Type: Article

References (34)

1. Gilligan DM, Cleland JGF, Oakley CM. The genetics of hypertrophic cardiomyopathy. Br Heart J. 1991;66:193-195.
2. Tanigawa G, Jarcho JA, Kass S, Solomon SD, Vosberg HP, Seidman JG, Seidman CE. A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene. Cell. 1990;62: 991-998.
3. Geisterfer-Lowrence AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain missense mutation. Cell. 1990;62:999-1006.
4. Watkins H, Rosenzweig A, Hwang D-S, Levi T, McKenna W, Seidman CE; Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108-1114.
5. Epstein ND, Lin HJ, Fananapazir L. Genetic evidence of dissociation (generational skips) of electrical from morphological forms of hypertrophic cardiomyopathy. Am J Cardiol. 1990;66:627-631.
6. Schwartz K, Beckmann J, Dufour C, Faure L, Fougerousse F, Carrier L, Hengstenberg C, Cohen D, Vosberg HP, Sacrez A, Ferriére M, Desnos M, Cambien F, Dubourg O, Komajda M. Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Circ Res. 1992;71:3-8.
7. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316:780-789, 844-852.
8. Cohen LS, Braunwald E. Ameloriation of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847-851.
9. Lefroy DC, de Silva R, Choudhury L, Uren NG, Crake T, Rhodes CG, Lammertsma AA, Boyd H, Patsalaos PN, Nihoyannopoulos P, Oakley CM, Jones T, Catmici PG. Diffuse reduction of myocardial beta adreno-ceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J Am Coll Cardiol. 1993;22:1653-1660.
10. Choudhury L, Guzzetti S, Lefroy DC, Nihoyannopoulos P, McKenna WJ, Oakley CM, Camici PG. Myocardial β adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart. 1996;75:50-54.
11. Araujo LI, Lammertsma AA, Rhodes CG, McFalls EO, Iida H, Rechavia E, Galassi A, de Silva R, Jones T, Maseri A. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation. 1991;83:875-885.
12. Iida H, Rhodes CG, de Silva R, Yamamoto Y, Araujo LI, Maseri A, Jones T. Myocardial tissue fraction: correction for partial volume effects and measure of tissue viability. J Nucl Med. 1991;32:2169-2175.
13. Rosenspire KC, Haka MS, van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, Wieland DM. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med. 1990;31:1328-1334.
14. Ranicar ASO, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM, Jones T. The on-line monitoring of continuously withdrawn blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. Med Prog Technol. 1991;17:259-264.
15. 11C]CGP 12177 as a preferred radioligand for the beta-adrenergic receptors. Appl Radiat Isot. 1991;42:621-628.
16. Delforge J, Syrota A, Lançon JP, Nakajima K, Loch C, Janier M, Vallois JM, Cayla J, Crouzel C. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177 and a new graphical method. J Nucl Med. 1991,32:739-748.
17. Taki J, Nakajima K, Bunko H, Simizu M, Muramori A, Hisada K. Whole-body distribution of iodine-123-metaiodobenzylguanidine in hypertrophic cardiomyopathy: significance of its washout from the heart. Eur J Nucl Med. 1990;17:264-268.
18. Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K. Quantitative analysis of 123-I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990;119:1329-1337.
19. 123(I)-metaiodobenzylguanidine in cardiomyopathy. Z Kardiol. 1988;77:278-281.
20. Casset Senon D, Phillipe L, Cosnay P, Lopez Moutault J, Turot Bracq V, Fauchier JP, Pettier JM. Isotopic study of myocardial perfusion and innervation in 28 patients with primary hypertrophic cardiomyopathy: relation to ventricular arrhythmia. Arch Mal Coeur Vaiss. 1994;87:475-483.
21. Shimizu M, Sugihara N, Kita Y, Shimizu K, Horita Y, Nakajima K, Taki J, Takeda R. Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy. Br Heart J. 1992;67:155-160.
22. 123I-metaiodobenzylguanidine. Kaku Igaku. 1990;27:33-38.
23. Brush JE, Eisenhofer G, Garty M, Still R, Maron BJ, Cannon RO, Panza JA, Epstein SE, Goldstein DS. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation. 1989;79:836-844.
24. Schwaiger M, Hutchins GD, Kalff V, Rosenspire K, Haka MS, Mallette S, Deeb GM, Abrams GD, Wieland D. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest. 1991;87:1681-1690.
25. Allman KC, Wieland DM, Muzik O, DeGrado TR, Wolfe ER, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol. 1993;22:368-375.
26. Mélon PG, Nguyen N, DeGrado TR, Mangner TJ, Wieland DM, Schwieger M. Imaging of cardiac neuronal function after cocaine exposure using carbon-11 hydroxyephedine and positron emission tomography. J Am Coll Cardiol. 1994;23:1693-1699.
27. DeGrado TR, Hutchins GD, Toorongian SA, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-meta-hydroxyephedrine: retention mechanisms and effects of norepinephrine. J Nucl Med. 1993;34: 1287-1293.
28. 11C]-m-hydroxyephedrine in the rat. Nucl Med Biol. 1997;24:417-424.
29. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ('small vessel') coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:545-557.
30. Spirito P, Maron BJ, Chiarella F, Bellotti P, Tramarin R, Pozzoli M, Vecchio C. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy. Circulation. 1985;72:310-316.
31. Camici PG, Chiriatti G, Lorenzoni R, Bellina RC, Gistri R, Italiani G, Parodi O, Salvadori PA, Nista N, Papi L. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol. 1991;17:879-886.
32. Merlet P, Delforge J, Syrota A, Angevin E, Maziere B, Crouzel C, Valette H, Loisance D, Castaigne A, Rande JL. Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation. 1993;87:1169-1178.
33. Kawai C, Yui Y, Hoshino T, Sasayama S, Matsumori A. Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy. J Am Coll Cardiol. 1983;2:834-840.
34. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray T, Mestroni L, Karwande SV. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.